Jasper Bos

M Ventures
Gustav Mahlerplein 102
Toyo lto Building, 20th Floor
1082 MA Amsterdam
The Netherlands

Jasper Bos joined Merck’s previous biopharma fund of M Ventures in 2009 and transitioned to Vice President leading the healthcare team for the current fund in 2016. At M Ventures, Jasper Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Lundbeck for close to US 1,100 bn, Calypso Biotech, Inthera, Metabomed and Asceneuron. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute. Jasper published over 35 articles on health economics, vaccines and mathematical modelling.

Portfolio Companies

more about
ARTSaVit
more about
Calypso Biotech
more about
Galecto Biotech
more about
Inthera
more about
iOmx
more about
Metabomed LTD
more about
ObsEva
more about
RaNA Therapeutics now Translate Bio
more about
Vaximm